Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;25(6):713-723.
doi: 10.2174/1389201025666230907145019.

Nanostructured Lipid Carriers Mediated Drug Delivery to Posterior Segment of Eye and their In-vivo Successes

Amit Kumar Singh  1   2 , Manish Kumar  3 , Prabhat Kumar Upadhyay  1
Affiliations
Review

Nanostructured Lipid Carriers Mediated Drug Delivery to Posterior Segment of Eye and their In-vivo Successes

Amit Kumar Singh et al. Curr Pharm Biotechnol. 2024.

Abstract

Background: The disease of the posterior segment of the eye is a major concern worldwide, and it affects more than 300 million people and leads to serious visual deterioration. The current treatment available is invasive and leads to serious eye complications. These shortcomings and patient discomfort lead to poor patient compliance. In the last decade, Nanostructured lipid carriers (NLC) have established a remarkable milestone in the delivery of drug substances to the posterior segment of the eye. Additionally, NLC can reduce the clearance due to adhesive properties which are imparted due to nano-metric size. This attribute might reduce the adverse effects associated with intravitreal therapy and thus enhance therapeutic efficacy, eventually raising patient adherence to therapy. The current review provides an inclusive account of NLC as a carrier to target diseases of the posterior segment of the eye.

Objective: The review focuses on the various barrier encountered in the delivery of drugs to the posterior segment of the eye and the detail about the physicochemical property of drug substances that are considered to be suitable candidates for encapsulation to lipid carriers. Therefore, a plethora of literature has been included in this review. The review is an attempt to describe methods adopted for assessing the in-vivo behavior that strengthens the potential of NLC to treat the disease of the posterior segment of the eye.

Conclusion: These NLC-based systems have proven to be a promising alternative in place of invasive intravitreal injections with improved patient compliance.

Keywords: NLC; eye; intravitreal therapy.; lipid carriers; nanostructure; posterior segment.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Lynch C.; Kondiah P.P.D.; Choonara Y.E.; du Toit L.C.; Ally N.; Pillay V.; Advances in biodegradable nano-sized polymer-based ocular drug delivery. Polymers 2019,11(8),1371 - DOI - PubMed
    1. Thrimawithana T.R.; Young S.; Bunt C.R.; Green C.; Alany R.G.; Drug delivery to the posterior segment of the eye. Drug Discov Today 2011,16(5-6),270-277 - DOI - PubMed
    1. Seah I.; Zhao X.; Lin Q.; Liu Z.; Su S.Z.Z.; Yuen Y.S.; Hunziker W.; Lingam G.; Loh X.J.; Su X.; Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases. Eye 2020,34(8),1341-1356 - DOI - PubMed
    1. Platania C.B.M.; Dei Cas M.; Cianciolo S.; Fidilio A.; Lazzara F.; Paroni R.; Pignatello R.; Strettoi E.; Ghidoni R.; Drago F.; Bucolo C.; Novel ophthalmic formulation of myriocin: Implications in retinitis pigmentosa. Drug Deliv 2019,26(1),237-243 - DOI - PubMed
    1. Araújo J.; Nikolic S.; Egea M.A.; Souto E.B.; Garcia M.L.; Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf B Biointerfaces 2011,88(1),150-157 - DOI - PubMed

MeSH terms

LinkOut - more resources